NGIO is critical. It must merge with the public vehicle and list/uplist to NASDAQ. That will infuse $$, value and increase assets under management. I stated about a week ago (maybe more) that I felt the 10K was not going to be the answer. I also stated that I was expecting pps between 1-1.25. We are still too far off from the div and NGIO so I don’t think we have bottomed out yet. Until I see 10/31 and 11/15 short numbers I won’t be convinced that those problems are behind us. Sadly I think we are headed to the .80s before div and NGIO. I don’t expect any problems with the div or NGIO but if either is postponed or cancelled it is going to be a long road back from where we land.
I feel it’s important to note that this is just my opinion and not based on fundamentals or charts or financials. It’s just where I feel we are right now. I personally believe we are WAY UNDERVALUED. I think that without NGIO we should be at about 150M and with about 250M. Given any progress on Merck colab or Altucell the sky is the limit.
“I believe, I believe, I know it’s silly but I believe”.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links